Table 2

Use cases for LASV diagnostics: needs based on target use and setting in a Lassa-affected country

Intended use caseTarget use setting/diagnostic needs
43210
National reference labReferral/regional hospitalDistrict hospitalsHealth centresHealth posts, field settings
Case detection and managementMDx*†
POC MDx*†
IA*†
MDx*†
POC MDx*†
IA*
POC MDx*
POC IA*
RDT*
SurveillanceMDx*† sequencing
IA*
MDx*
POC MDx*
IA*
POC MDx*
POC IA*
RDT*
RDT*
Outbreak responseMDx*†
POC MDx*† sequencing
IA*
MDx*
POC MDx*
IA*
POC MDx*
POC IA*
RDT*
RDT*RDT*
Clinical trials (vaccine, therapeutics)MDx*†
POC MDx*† sequencing
IA*†
MDx*†
POC MDx*†
IA*†
POC MDx*
POC IA*
  • *Requires pan-LASV detection.

  • †Requires pan-VHF differentiation.

  • IA, immunoassay (eg, ELISA); LASV, Lassa virus; MDx, molecular diagnostics (eg, reverse transcriptase PCR); POC, point-of-care or near-patient; RDT, rapid diagnostic test (eg, lateral flow immunoassay); VHF, Viral haemorrhagic fever.